Abstract

Introduction: Volume overload is a known risk factor for cardiovascular disease and stroke in hemodialysis patients. The use of fibroblast growth factor 23 (FGF23) as a volume overload marker has been validated in multiple studies. Objectives: This is a prospective cross-sectional study considering the association between FGF23 and bioimpedance-measured volume overload in hemodialysis patients. Patients and Methods: Bioimpedance analysis was performed on 43 hemodialysis patients at the end of hemodialysis to evaluate the remaining volume overload and serum FGF23 was measured before hemodialysis. Results: The results indicated no significant correlation between mean serum FGF23 levels and volume overload in hemodialysis patients (P=0.824). Conclusion: Although this study did not show any association between volume overload and FGF23, further studies are needed to define the role of FGF23 as a volume overload marker.

Highlights

  • Volume overload is a known risk factor for cardiovascular disease and stroke in hemodialysis patients

  • The average fluid overload of patients determined by bioimpedance analysis (BIA) was 0.560±0.93 liter at the end of dialysis (Figure 1)

  • There was no difference between males and females in terms of dialysis time, blood pressure, fluid overload, fibroblast growth factor 23 (FGF23), and Kt/V

Read more

Summary

Introduction

Volume overload is a known risk factor for cardiovascular disease and stroke in hemodialysis patients. Objectives: This is a prospective cross-sectional study considering the association between FGF23 and bioimpedance-measured volume overload in hemodialysis patients. Patients and Methods: Bioimpedance analysis was performed on 43 hemodialysis patients at the end of hemodialysis to evaluate the remaining volume overload and serum FGF23 was measured before hemodialysis. Results: The results indicated no significant correlation between mean serum FGF23 levels and volume overload in hemodialysis patients (P = 0.824). Cardiovascular disease and stroke are the principal causes of morbidity and mortality in hemodialysis patients [2]. Studies have indicated that hypertension is the major cause of cardiovascular and cerebrovascular adverse events in hemodialysis patients which, in turn, has been linked to chronic volume overload in these patients [3,4]. Cost and complexity limit using these methods [2]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call